Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Problems Still Abound For FDA's Accredited Persons Inspection Program

This article was originally published in The Silver Sheet

Executive Summary

FDA'S ACCREDITED PERSONS (AP) INSPECTION PROGRAM IS STRUGGLING because of financial costs to manufacturers, difficulties in getting third-party auditors trained and industry apathy, experts say. Since it was created in 2003, only about 90 inspections have been completed under the program, which allows manufacturers to hire agency-approved auditors to conduct FDA quality system inspections. "It would be very helpful if industry really embraced the program, but the bottom line is that industry is not embracing it," David Kalins, CDRH's AP program coordinator says. Two of the 16 auditing firms certified by the agency to perform AP inspections - Underwriters Laboratories and TUV SÜD America - talk about the challenges they face. Meanwhile, an updated FDA guidance on the AP program explains statutory changes made in 2007 that make it easier for firms to take part

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT036412

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel